New Drug Beats Chemotherapy for Rare Pancreatic Cancer in Major Trial

The New England Journal of Medicine (NEJM) has posted results from the phase 3 RASolute 302 trial, showing that daraxonrasib — a type of drug known as a RAS(ON) inhibitor, which works by blocking a faulty protein that drives cancer growth — extended both overall survival and the time patients lived without their disease getting worse. The trial focused on patients with metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, whose disease had already been treated once before.

Pancreatic cancer is notoriously difficult to treat, and options after a first round of treatment are limited. So a drug showing a meaningful survival advantage over standard chemotherapy at this stage is being watched closely by oncologists.

The NEJM described daraxonrasib as a RAS(ON) inhibitor — a class of drug that targets an activated form of the RAS protein, which is mutated in the bulk of pancreatic cancers and has long been considered extremely hard to block with medication. The trial’s full results and a research summary have been made available by the journal.

No specific figures on survival benefit were included in the NEJM’s post, and the full data sit behind the journal’s publication rather than in the social media announcement. Patients and families should not draw conclusions about individual treatment options from trial-level results — what works across a study population doesn’t automatically apply to any one person’s situation.

Anyone concerned about pancreatic cancer symptoms — which the NHS says can include jaundice, unexplained weight loss, and persistent upper abdominal or back pain — should contact their GP in the first instance. For urgent concerns, NHS 111 is available around the clock.

Key information

• GP referral: Speak to your GP if you have persistent symptoms such as jaundice, unexplained weight loss, or upper abdominal pain
• NHS 111: Available 24 hours a day, seven days a week, for urgent but non-emergency health concerns
• Pancreatic Cancer UK helpline: 0808 801 0707, free to call